Boehringer Ingelheim Corporation To Present Highly Anticipated Phase III Data In IPF And COPD At American Thoracic Society International Conference
Published: Apr 30, 2014
For media outside UK, U.S. and Canada
Boehringer Ingelheim announced today that the first results of the two confirmatory Phase III INPULSISTM trials, investigating nintedanib* in the treatment of idiopathic pulmonary fibrosis (IPF), will be presented at the 2014 American Thoracic Society (ATS) International Conference taking place 16 – 21 May in San Diego. IPF is a rare, debilitating and fatal lung disease for which treatment options are limited.
Help employers find you! Check out all the jobs and post your resume.